

(PRE-FILED)

By: **Delegates Pendergrass, Goldwater, Hubbard, Madaleno, and Mandel**

Requested: August 12, 2004

Introduced and read first time: January 12, 2005

Assigned to: Health and Government Operations

Committee Report: Favorable with amendments

House action: Adopted

Read second time: March 1, 2005

CHAPTER _____

1 AN ACT concerning

2 **Health - Clinical Trials Data Bank**

3 FOR the purpose of requiring a ~~certain clinical trial to be listed in~~ certain sponsor to
4 submit to the Clinical Trials Data Bank of the U.S. Department of Health and
5 Human Services certain information regarding a certain clinical trial before a
6 ~~certain~~ the sponsor may permit any person to enroll participants in the clinical
7 trial; providing for a certain exception; prohibiting a person from conducting a
8 clinical trial in violation of this Act; prohibiting certain requirements pertaining
9 to the Clinical Trials Data Bank from affecting providing that this Act may not
10 be construed to affect certain existing statutory requirements; authorizing the
11 Office of the Attorney General, under certain circumstances, to seek certain
12 relief to prevent the conduct of a clinical trial ~~and to petition a court to impose a~~
13 ~~certain fine; establishing certain criminal penalties for conducting a clinical~~
14 ~~trial without listing the clinical trial on the Clinical Trials Data Bank in~~
15 violation of this Act; requiring the Office of the Attorney General to report to the
16 General Assembly, on or before a certain date and annually thereafter, on
17 certain violations and certain actions of the Office; defining certain terms; and
18 generally relating to ~~listing of~~ the submission of information regarding clinical
19 trials ~~in~~ to the Clinical Trials Data Bank.

20 BY adding to

21 Article - Health - General

22 Section 13-2101 through 13-2105 to be under the new subtitle "Subtitle 21.

23 Clinical Trials Data Bank"

24 Annotated Code of Maryland

25 (2000 Replacement Volume and 2004 Supplement)

1 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF
2 MARYLAND, That the Laws of Maryland read as follows:

3 **Article - Health - General**

4 SUBTITLE 21. CLINICAL TRIALS DATA BANK.

5 13-2101.

6 (A) IN THIS SUBTITLE THE FOLLOWING WORDS HAVE THE MEANINGS
7 INDICATED.

8 (B) "CLINICAL TRIAL" MEANS:-

9 ~~(1) A RESEARCH STUDY IN HUMAN VOLUNTEERS TO ANSWER SPECIFIC~~
10 ~~HEALTH QUESTIONS; AND~~

11 ~~(2) A CLINICAL TRIAL FOR TO TEST THE EFFECTIVENESS OF DRUGS,~~
12 ~~INCLUDING BIOLOGICAL DRUG PRODUCTS, TO TREAT SERIOUS OR~~
13 ~~LIFE-THREATENING DISEASES AND CONDITIONS CONDUCTED UNDER THE U.S. FOOD~~
14 ~~AND DRUG ADMINISTRATION'S INVESTIGATIONAL NEW DRUG REGULATIONS (21 CFR~~
15 ~~PART 312).~~

16 (C) "DATA BANK" MEANS THE CLINICAL TRIALS DATA BANK IN THE U.S.
17 DEPARTMENT OF HEALTH AND HUMAN SERVICES ESTABLISHED UNDER ~~SECTION §~~
18 ~~113 OF THE FEDERAL~~ FOOD AND DRUG ADMINISTRATION MODERNIZATION ACT OF
19 1997.

20 (D) "SERIOUS OR LIFE-THREATENING DISEASE OR CONDITION" MEANS A
21 DISEASE OR CONDITION THAT HAS BEEN IDENTIFIED OR DESCRIBED AS SERIOUS OR
22 LIFE-THREATENING IN THE PUBLISHED GUIDANCE OF THE U.S. FOOD AND DRUG
23 ADMINISTRATION RELATING TO THE CLINICAL TRIALS DATA BANK.

24 ~~(D)~~ (E) "SPONSOR" MEANS THE NAME OF THE SPONSORING ORGANIZATION
25 THAT TAKES RESPONSIBILITY FOR AND INITIATES A CLINICAL TRIAL PERSON THAT
26 HOLDS THE INVESTIGATIONAL NEW DRUG EXEMPTION UNDER WHICH A CLINICAL
27 TRIAL WILL BE CONDUCTED IN ACCORDANCE WITH APPLICABLE REGULATIONS OF
28 THE U.S. FOOD AND DRUG ADMINISTRATION.

29 13-2102.

30 NOTHING IN THIS SUBTITLE MAY BE CONSTRUED TO AFFECT THE
31 REQUIREMENTS UNDER SUBTITLE 20 OF THIS TITLE.

32 13-2103.

33 ~~BEFORE A SPONSOR MAY ENROLL PARTICIPANTS IN A CLINICAL TRIAL IN THE~~
34 ~~STATE, THE CLINICAL TRIAL SHALL BE LISTED IN THE DATA BANK~~

1 (A) EXCEPT AS PROVIDED IN SUBSECTION (B) OF THIS SECTION, A SPONSOR
 2 MAY NOT PERMIT ANY PERSON TO ENROLL A PARTICIPANT IN A CLINICAL TRIAL IN
 3 THE STATE UNLESS, NOT LATER THAN 21 DAYS AFTER A CLINICAL TRIAL HAS BEEN
 4 OPENED TO ENROLLMENT, THE SPONSOR HAS SUBMITTED TO THE DATA BANK:

5 (1) A DESCRIPTION OF THE PURPOSE OF AN EXPERIMENTAL DRUG USED
 6 IN THE CLINICAL TRIAL;

7 (2) THE ELIGIBILITY CRITERIA FOR PARTICIPATION IN THE CLINICAL
 8 TRIAL;

9 (3) A DESCRIPTION OF THE LOCATION OF CLINICAL TRIAL SITES IN THE
 10 STATE; AND

11 (4) IDENTIFICATION OF A POINT OF CONTACT FOR INDIVIDUALS WHO
 12 WANT TO ENROLL IN THE CLINICAL TRIAL.

13 (B) IF A CLINICAL TRIAL IS EXEMPT FROM LISTING IN THE DATA BANK
 14 BECAUSE THE SPONSOR OF THE CLINICAL TRIAL HAS SUBMITTED A DETAILED
 15 CERTIFICATION TO THE SECRETARY OF HEALTH AND HUMAN SERVICES AS
 16 AUTHORIZED BY § 113 OF THE FEDERAL FOOD AND DRUG ADMINISTRATION
 17 MODERNIZATION ACT OF 1997, THE SPONSOR NEED NOT SUBMIT THE INFORMATION
 18 SPECIFIED IN SUBSECTION (A) OF THIS SECTION.

19 13-2104.

20 (A) A PERSON MAY NOT CONDUCT A CLINICAL TRIAL IN VIOLATION OF THIS
 21 SUBTITLE.

22 (B) THE OFFICE OF THE ATTORNEY GENERAL MAY:

23 (1) ~~SEEK APPROPRIATE INJUNCTIVE OR OTHER RELIEF TO PREVENT~~
 24 ~~THE CONDUCT OF A CLINICAL TRIAL IN VIOLATION OF THIS SUBTITLE; AND~~

25 (2) ~~PETITION A COURT, IN A CRIMINAL ACTION DESCRIBED UNDER §~~
 26 ~~13-2105 OF THIS SUBTITLE, TO IMPOSE A FINE NOT TO EXCEED \$1,000 FOR EACH DAY~~
 27 ~~THAT A CLINICAL TRIAL PROCEEDS WITHOUT BEING LISTED IN THE DATA BANK.~~

28 13-2105.

29 (A) ~~A PERSON MAY NOT CONDUCT A CLINICAL TRIAL IN VIOLATION OF THIS~~
 30 ~~SUBTITLE.~~

31 (B) ~~A PERSON WHO VIOLATES THIS SECTION IS GUILTY OF A MISDEMEANOR~~
 32 ~~AND ON CONVICTION IS SUBJECT TO A FINE NOT TO EXCEED \$1,000 FOR EACH DAY~~
 33 ~~THAT A CLINICAL TRIAL PROCEEDS WITHOUT BEING LISTED IN THE DATA BANK.~~

34 ON OR BEFORE DECEMBER 31, 2006, AND ANNUALLY THEREAFTER, THE OFFICE
 35 OF THE ATTORNEY GENERAL SHALL REPORT, IN ACCORDANCE WITH § 2-1246 OF THE
 36 STATE GOVERNMENT ARTICLE, TO THE GENERAL ASSEMBLY ON THE NUMBER AND

1 TYPES OF VIOLATIONS OF THIS SUBTITLE THAT OCCURRED DURING THE PREVIOUS
2 CALENDAR YEAR AND THE ACTIONS TAKEN BY THE OFFICE IN RESPONSE TO THE
3 VIOLATIONS.

4 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect
5 October 1, 2005.